Medication info
Daplfloem Sustained Release Tablet 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Daplfloem Sustained Release Tablet 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Propanediol Hydrate›12.3mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Youngjin Pharmaceutical Co., Ltd.
Appearance
Pink, double convex, oval-shaped sustained release film-coated tablet
Packaging
30 tablets/box[(10 tablets/PTP(Alu-Alu)X3)]
Approval status
Active

MFDS item code 202300428 · Approved 2023.01.31 · Insurance code 642405150

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Ingredients

Manufacturer
Youngjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes with difficult blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used as an adjunct to diet and exercise to assist with blood sugar control in adult patients with type 2 diabetes taking both dapagliflozin and metformin. In patients with type 2 diabetes whose blood sugar is not adequately controlled and who have cardiovascular disease or risk factors, the impact of dapagliflozin on the occurrence of cardiovascular events should be referenced from the professional information. This medication aids in diabetes management and blood sugar improvement to maintain health.

How to take

Adult dose

The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients with no prior history of diabetes drug treatment who do not achieve adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior history of diabetes drug treatment, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching from combination therapy with dapagliflozin and metformin to this drug, this drug may be initiated at the doses of dapagliflozin and metformin they were previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other glucose-lowering drugs. Because changes may alter glycemic control, any change in treatment in patients with type 2 diabetes should be made under close monitoring. This drug should be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass that resembles a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or greater and less than 60 mL/min/1.73 m2 who do not have other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this drug is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this drug should be discontinued immediately. Renal function should be evaluated every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this drug should be used with caution as age increases (see Precautions, 9. Administration to elderly patients).

Precautions

This medication helps in controlling blood sugar levels. However, it can rarely cause a serious condition called lactic acidosis, so caution is advised. When used with other diabetes medications, there may be a risk of hypoglycemia, requiring dosage adjustments. Patients with impaired kidney function or specific serious diseases, pregnant or breastfeeding women should not use this medication. Furthermore, the medication should be temporarily discontinued during periods of dehydration, severe infection, or unstable physical conditions around surgery. Regular monitoring of kidney function and fluid status is required while using this medication, especially for elderly patients or those with decreased kidney function. Blood pressure and symptoms should be closely monitored as low blood pressure or dehydration may occur. Side effects may include genital infections, urinary tract infections, hypoglycemia, dizziness, fluid depletion, etc. If any signs of infection occur, immediate medical attention is needed, and one should also be alert for symptoms of hypoglycemia. This medication can lower vitamin B12 levels, so checking vitamin B12 concentration is recommended for long-term usage. Alcohol consumption may increase the risk of side effects from this medication, so it should be avoided. Additionally, this medication can interact with other drugs, so inform your healthcare provider if you are taking any other medications, especially diuretics or blood pressure medications. Pregnant women or those planning to become pregnant should not use this medication, and breastfeeding women should also avoid its use. In case of overdose, immediate visit to a medical institution is necessary for appropriate treatment, as this medication is excreted through the kidneys, requiring careful management of kidney function. While taking this medication, dizziness may occur when driving or operating machinery, so caution is advised, and it should be kept out of reach of children.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • lower back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased kidney creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burns
  • wrist fracture
  • gastrointestinal stromal tumor
  • pulmonary malignant neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • increased alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • itchiness
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air and moisture, so it must be stored in a tightly sealed container. It is recommended to maintain a storage temperature between 1 to 30 degrees Celsius. This will help preserve the medication's efficacy.

Appearance and packaging

Appearance

Pink, double convex, oval-shaped sustained release film-coated tablet

Package unit

30 tablets/box[(10 tablets/PTP(Alu-Alu)X3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.